{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:22:18Z","timestamp":1772911338946,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Huazhong Univ. Sci. Technol. [Med. Sci.]"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s11596-013-1063-5","type":"journal-article","created":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T18:44:33Z","timestamp":1360262673000},"page":"1-14","source":"Crossref","is-referenced-by-count":13,"title":["A meta-analysis of salicylates for type 2 diabetes mellitus"],"prefix":"10.1007","volume":"33","author":[{"given":"Fang","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-ying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"issue":"suppl1","key":"1063_CR1","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1331\/JAPhA.2009.09077","volume":"49","author":"R.K. Campbell","year":"2009","unstructured":"Campbell RK. Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc, 2009,49(suppl 1):s3\u2013s9","journal-title":"J Am Pharm Assoc"},{"issue":"7\u20138","key":"1063_CR2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1345\/aph.1M483","volume":"44","author":"M.M. Rumore","year":"2010","unstructured":"Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother, 2010,44(7\u20138):1207\u20131221","journal-title":"Ann Pharmacother"},{"issue":"25","key":"1063_CR3","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jacc.2010.04.003","volume":"55","author":"M. Pignone","year":"2010","unstructured":"Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol, 2010,55(25):2878\u20132886","journal-title":"J Am Coll Cardiol"},{"issue":"suppl1","key":"1063_CR4","doi-asserted-by":"crossref","first-page":"s72","DOI":"10.2337\/diacare.27.2007.S72","volume":"27","author":"American Diabetes Association.","year":"2004","unstructured":"American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care, 2004,27(suppl 1):s72\u2013s73","journal-title":"Diabetes Care"},{"issue":"1","key":"1063_CR5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1752-8062.2008.00026.x","volume":"1","author":"A.B. Goldfine","year":"2008","unstructured":"Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci, 2008,1(1): 36\u201343","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1063_CR6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.mehy.2009.12.027","volume":"75","author":"M.F. McCarty","year":"2010","unstructured":"McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses, 2010,75(3): 276\u2013281","journal-title":"Med Hypotheses"},{"issue":"7111","key":"1063_CR7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(59)91534-X","volume":"2","author":"G.R. Fearnley","year":"1959","unstructured":"Fearnley GR, Vincent CT, Chakrabarti R. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet, 1959,2(7111):1067","journal-title":"Lancet"},{"issue":"7371","key":"1063_CR8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(64)91042-6","volume":"2","author":"D. Ogaston","year":"1964","unstructured":"Ogaston D, McAndrew GM. Fibrinolysis in obesity. Lancet, 1964,2(7371):1205\u20131207","journal-title":"Lancet"},{"issue":"4","key":"1063_CR9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0368-1319(68)80028-6","volume":"8","author":"C.S. Grace","year":"1968","unstructured":"Grace CS, Goldrick RB. Fibrinolysis and body build. Interrelationships between blood fibrinolysis, body composition and parameters of lipid and carbohydrate metabolism. J Atheroscler Res, 1968,8(4):705\u2013719","journal-title":"J Atheroscler Res"},{"issue":"5091","key":"1063_CR10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","volume":"259","author":"G.S. Hotamisligil","year":"1993","unstructured":"Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-\u03b1: direct role in obesity-linked insulin resistance. Science, 1993,259(5091): 87\u201391","journal-title":"Science"},{"issue":"35","key":"1063_CR11","doi-asserted-by":"crossref","first-page":"26 055","DOI":"10.1016\/S0021-9258(19)74276-8","volume":"268","author":"R. Feinstein","year":"1993","unstructured":"Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-\u03b1 suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem, 1993,268(35):26 055\u201326 058","journal-title":"J Biol Chem"},{"issue":"11","key":"1063_CR12","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2337\/diabetes.43.11.1271","volume":"43","author":"G.S. Hotamisligil","year":"1994","unstructured":"Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 1994,43(11):1271\u20131278","journal-title":"Diabetes"},{"issue":"7","key":"1063_CR13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"S.E. Shoelson","year":"2006","unstructured":"Shoelson SE, LEE J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest, 2006,116(7):1793\u20131801","journal-title":"J Clin Invest"},{"issue":"10","key":"1063_CR14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00109-002-0383-x","volume":"80","author":"W. Ebstein","year":"2002","unstructured":"Ebstein W. Invited comment on W. Ebstein: On the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J Mol Med, 2002,80(10):618\u2013619","journal-title":"J Mol Med"},{"issue":"2100","key":"1063_CR15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/bmj.1.2100.760","volume":"1","author":"R.T. Williamson","year":"1901","unstructured":"Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J, 1901,1(2100):760\u2013762","journal-title":"Br Med J"},{"issue":"5053","key":"1063_CR16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/bmj.2.5053.1071","volume":"2","author":"J. Reid","year":"1957","unstructured":"Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. Br Med J, 1957,2(5053):1071\u20131074","journal-title":"Br Med J"},{"issue":"4Pt1","key":"1063_CR17","first-page":"418","volume":"8","author":"A. Hecht","year":"1959","unstructured":"Hecht A, Goldner MG. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism, 1959,8(4Pt 1): 418\u2013428","journal-title":"Metabolism"},{"issue":"5","key":"1063_CR18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2337\/diab.9.5.392","volume":"9","author":"S.G. Gilgore","year":"1960","unstructured":"Gilgore SG. The influence of salicylate on hyperglycemia. Diabetes, 1960,9(5):392\u2013393","journal-title":"Diabetes"},{"issue":"6","key":"1063_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","volume":"152","author":"A.B. Goldfine","year":"2010","unstructured":"Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes. Ann Intern Med, 2010,152(6):346\u2013357","journal-title":"Ann Intern Med"},{"issue":"2","key":"1063_CR20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2337\/dc07-1338","volume":"31","author":"A. Fleischman","year":"2008","unstructured":"Fleischman A, Bernier R, Shoelson SE. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care, 2008,31(2):289\u2013294","journal-title":"Diabetes Care"},{"issue":"3","key":"1063_CR21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-008-1239-x","volume":"52","author":"J. Koska","year":"2008","unstructured":"Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomized double-blind placebo-controlled study. Diabetologia, 2008,52(3):385\u2013393","journal-title":"Diabetologia"},{"issue":"9","key":"1063_CR22","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.108.804294","volume":"119","author":"G.L. Pierce","year":"2009","unstructured":"Pierce GL, Lesniewski LA, Lawson BR, et al. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight\/ obese middle-aged and older humans. Circulation, 2009,119(9):1284\u20131292","journal-title":"Circulation"},{"key":"1063_CR23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J.P. Higgins","year":"2008","unstructured":"Higgins JP, Altman DG. Assessing risk of bias in included studies. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 ed. England: John Wiley & Sons Ltd, 2008,206","edition":"5.0.2 ed."},{"issue":"1","key":"1063_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"A.R. Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996,17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"1063_CR25","first-page":"206","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J.J. Deeks","year":"2008","unstructured":"Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 ed. England: John Wiley & Sons Ltd, 2008,206","edition":"5.0.2 ed"},{"key":"1063_CR26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J.P. Higgins","year":"2008","unstructured":"Higgins JP, Deeks JJ, Altman DG. Special topics in statis tics. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 ed. England: John Wiley & Sons Ltd, 2008,206","edition":"5.0.2 ed."},{"key":"1063_CR27","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J. Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J, 2008,337:a1840","journal-title":"Br Med J"},{"issue":"7","key":"1063_CR28","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.2337\/dc07-0187","volume":"30","author":"E.G. Camargo","year":"2007","unstructured":"Camargo EG, Weinert LS, Lavinsky J, et al. The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Diabetes Care, 2007, 30(7):e66","journal-title":"Diabetes Care"},{"issue":"1\u20132","key":"1063_CR29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2008.01.029","volume":"391","author":"E.G. Camargo","year":"2008","unstructured":"Camargo EG, Pedrini RO, Gross JL, et al. Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Clin Chim Acta, 2008,391(1\u20132):120\u2013122","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1063_CR30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archopht.1992.01080150037023","volume":"110","author":"E.Y. Chew","year":"1992","unstructured":"Chew EY, Williams GA, Burton TC, et al. Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16. Arch Ophthalmol, 1992,110(3):339\u2013342","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1063_CR31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/archopht.1995.01100010054020","volume":"113","author":"E.Y. Chew","year":"1995","unstructured":"Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous\/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol, 1995,113(3):52\u201355","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"1063_CR32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.20.5.832","volume":"20","author":"I. Contreras","year":"1997","unstructured":"Contreras I, Reiser KM, Martinez N, et al. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care, 1997,20(5): 832\u2013835","journal-title":"Diabetes Care"},{"issue":"3","key":"1063_CR33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ndt\/18.3.539","volume":"18","author":"P. Gaede","year":"2003","unstructured":"Gaede P, Hansen HP, Parving HH, et al. Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant, 2003,18(3):539\u2013542","journal-title":"Nephrol Dial Transplant"},{"issue":"9118","key":"1063_CR34","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L. Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998,351(9118):1755\u20131762","journal-title":"HOT Study Group. Lancet"},{"issue":"8","key":"1063_CR35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1463-1326.2007.00794.x","volume":"10","author":"M.M. Hovens","year":"2008","unstructured":"Hovens MM, Snoep JD, Groeneveld Y, et al. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes Metab, 2008,10(8): 668\u2013674","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1063_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/003655902753679454","volume":"36","author":"P. Khajehdehi","year":"2002","unstructured":"Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol, 2002,36(2):145\u2013148","journal-title":"Scand J Urol Nephrol"},{"issue":"4","key":"1063_CR37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0049-3848(99)00168-1","volume":"97","author":"M. Kodama","year":"2000","unstructured":"Kodama M, Yamasaki Y, Sakamoto K, et al. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res, 2000,97(4):239\u2013245","journal-title":"Thromb Res"},{"issue":"1","key":"1063_CR38","first-page":"46","volume":"139","author":"N.L. Mork","year":"1983","unstructured":"Mork NL, Robertson RP. Effects of nonsteroidal antiinflammatory drugs in conventional dosage on glucose homeostasis in patients with diabetes. West J Med, 1983,139(1):46\u201349","journal-title":"West J Med"},{"key":"1063_CR39","doi-asserted-by":"crossref","unstructured":"Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes, 1989,38(4):491\u2013498","DOI":"10.2337\/diabetes.38.4.491"},{"key":"1063_CR40","doi-asserted-by":"crossref","unstructured":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. Steering Committee of the Physicians\u2019 Health Study Research Group. N Engl J Med, 1989,321(3):129\u2013135","DOI":"10.1056\/NEJM198907203210301"},{"key":"1063_CR41","doi-asserted-by":"crossref","unstructured":"Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991,98(5 Suppl):757\u2013765","DOI":"10.1016\/S0161-6420(13)38010-5"},{"key":"1063_CR42","doi-asserted-by":"crossref","unstructured":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA, 1992,268(10):1292\u20131300","DOI":"10.1001\/jama.1992.03490100090033"},{"issue":"18","key":"1063_CR43","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H. Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008,300(18):2134\u20132141","journal-title":"JAMA"},{"issue":"3","key":"1063_CR44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0026-0495(81)90155-4","volume":"30","author":"R.L. Prince","year":"1981","unstructured":"Prince RL, Larkins RG, Alford FP. The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects. Metab Clin Exp, 1981,30(3):293\u2013298","journal-title":"Metab Clin Exp"},{"issue":"13","key":"1063_CR45","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"P.M. Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 2005,352(13):1293\u20131304","journal-title":"N Engl J Med"},{"issue":"12","key":"1063_CR46","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","volume":"26","author":"M. Sacco","year":"2003","unstructured":"Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care, 2003,26(12):3264\u20133272","journal-title":"Diabetes Care"},{"issue":"2","key":"1063_CR47","first-page":"31","volume":"25","author":"J.R. He","year":"1995","unstructured":"He JR, Ni AM, Zhang HG. Effect of captopril with aspirin on inceptive diabetic nephropathy. J Lanzhou Med Col (Chinese), 1995,25(2):31\u201333","journal-title":"J Lanzhou Med Col (Chinese)"},{"issue":"1","key":"1063_CR48","first-page":"28","volume":"4","author":"W. Zhang","year":"2002","unstructured":"Zhang W, Chen Y, Liu S, et al. The effect of aspirin to type 2 diabetic heart rate variability. J Shenyang Med Col (Chinese), 2002,4(1):28\u201330","journal-title":"J Shenyang Med Col (Chinese)"},{"issue":"6","key":"1063_CR49","first-page":"335","volume":"16","author":"W.M. Li","year":"1998","unstructured":"Li WM, Xiong YG, Wang Z, et al. Clinical study on the prevention and treatment of NIDDM retinopathy with small dose aspirin. J Pharmac Prac (Chinese), 1998,16(6): 335\u2013337","journal-title":"J Pharmac Prac (Chinese)"},{"issue":"4","key":"1063_CR50","first-page":"333","volume":"13","author":"R.L. Li","year":"2000","unstructured":"Li RL, Xie CC. Analysis of 30 diabetic patients treated with aspirin. J Handan Med Col (Chinese), 2000,13(4): 333","journal-title":"J Handan Med Col (Chinese)"},{"issue":"4","key":"1063_CR51","first-page":"645","volume":"6","author":"L. Lin","year":"2006","unstructured":"Lin L, Zhao YL, Shi FJ. Dynamic changes of IL-8 and CRP in senile type 2 diabetic patients after adminsteration of aspirin. China Trop Med (Chinese), 2006,6(4):645\u2013646","journal-title":"China Trop Med (Chinese)"},{"issue":"6","key":"1063_CR52","first-page":"721","volume":"36","author":"L. Wang","year":"2005","unstructured":"Wang L, Zhao XW, Zhang Y, et al. Serum C-reactive protein levels in type 2 diabetes patients and effects of aspirin on C-reactive protein. J Shanxi Med Univ (Chinese), 2005,36(6):721\u2013723","journal-title":"J Shanxi Med Univ (Chinese)"},{"issue":"2","key":"1063_CR53","first-page":"131","volume":"3","author":"A.W. Dong","year":"2002","unstructured":"Dong AW. Clinical analysis of decrease of HbA1c level by aspirin on 55 diabetic patients. Pract Clin Med (Chinese), 2002,3(2):131\u2013132","journal-title":"Pract Clin Med (Chinese)"},{"issue":"4","key":"1063_CR54","first-page":"297","volume":"28","author":"X.Z. Jiang","year":"2009","unstructured":"Jiang XZ, Gu Z, Zhou B, et al. Effects of aspirin on inflammatory factors of type 2 diabetes mellitus patients. Chin J New Drugs Clin Rem (Chinese), 2009,28(4): 297\u2013300","journal-title":"Chin J New Drugs Clin Rem (Chinese)"},{"issue":"2","key":"1063_CR55","first-page":"186","volume":"26","author":"S.Q. Lu","year":"2004","unstructured":"Lu SQ. Clinical effectiveness of enalapril and aspirin on incipient diabetic nephropathy. Guangxi Med J (Chinese), 2004,26(2):186\u2013188","journal-title":"Guangxi Med J (Chinese)"},{"issue":"9","key":"1063_CR56","first-page":"687","volume":"26","author":"N.H. Chen","year":"2000","unstructured":"Chen NH, Zhou P, He RH, et al. Relationship between change in content of platelet \u03b1-granule membrane protein and nephropathy in type 2 diabetic patients. Jiangsu Med J (Chinese), 2000,26(9):687\u2013689","journal-title":"Jiangsu Med J (Chinese)"},{"issue":"7501","key":"1063_CR57","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(67)92842-5","volume":"1","author":"J.B. Field","year":"1967","unstructured":"Field JB, Boyle C, Remer A. Effect of salicylate infusion on plasma-insulin and glucose tolerance in healthy persons and mild diabetics. Lancet, 1967,1(7501): 1191\u20131194","journal-title":"Lancet"},{"issue":"3","key":"1063_CR58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1172\/JCI108827","volume":"60","author":"R.P. Robertson","year":"1977","unstructured":"Robertson RP, Chen M. A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus. J Clin Invest, 1977,60(3):747\u2013753","journal-title":"J Clin Invest"},{"issue":"9","key":"1063_CR59","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF00291974","volume":"28","author":"P.R. Bratusch-Marrain","year":"1985","unstructured":"Bratusch-Marrain PR, Vierhapper H, Komjati M, et al. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia, 1985,28(9):671\u2013676","journal-title":"Diabetologia"},{"issue":"12","key":"1063_CR60","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/diabetes.27.12.1196","volume":"27","author":"P. Micossi","year":"1978","unstructured":"Micossi P, Pontiroli AE, Baron SH, et al. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes, 1978,27(12):1196\u20131204","journal-title":"Diabetes"},{"issue":"5","key":"1063_CR61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/(SICI)1096-9136(199705)14:5<405::AID-DIA360>3.0.CO;2-H","volume":"14","author":"A.A. Mubarak","year":"1997","unstructured":"Mubarak AA. Is low-dose aspirin a useful adjuvant therapy in the treatment of NIDDM? Diabet Med, 1997,14(5): 405\u2013406","journal-title":"Diabet Med"},{"issue":"8165","key":"1063_CR62","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(80)90945-9","volume":"1","author":"C.R. Strakosch","year":"1980","unstructured":"Strakosch CR, Jefferys DB, Keen H. Blockade of chlorpropamide alcohol flush by aspirin. Lancet, 1980,1(8165): 394\u2013396","journal-title":"Lancet"},{"issue":"1","key":"1063_CR63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0029-1210791","volume":"92","author":"J. Skrha","year":"1988","unstructured":"Skrha J, Hilgertova J, Svacina S, et al. Insulin receptors and glucose homeostasis in type 2 diabetics influenced by acetyl-salicylic acid treatment. Exp Clin Endocrinol, 1988,92(1):119\u2013122","journal-title":"Exp Clin Endocrinol"},{"issue":"10","key":"1063_CR64","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI0214955","volume":"109","author":"R.S. Hundal","year":"2002","unstructured":"Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest, 2002,109(10):1321\u20131326","journal-title":"J Clin Invest"},{"issue":"4","key":"1063_CR65","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1055\/s-0038-1660157","volume":"54","author":"A.H. Hopper","year":"1985","unstructured":"Hopper AH, Tindall H, Davies JA. Effect of aspirin on glucose tolerance and insulin levels in patients with type 2 diabetes mellitus. Thromb Haemost, 1985,54(4):895","journal-title":"Thromb Haemost"},{"issue":"6","key":"1063_CR66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2265.1983.tb00599.x","volume":"18","author":"H. Vierhapper","year":"1983","unstructured":"Vierhapper H, Bratusch-Marrain P, Waldhausl W, et al. Increased secretion of insulin but unchanged secretion of growth hormone in hyperglycaemic type II diabetics treated with acetyl-salicylic acid. Clin Endocrinol (Oxf), 1983,18(6):613\u2013619","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1063_CR67","first-page":"6","volume":"239","author":"G. Tornvall","year":"1980","unstructured":"Tornvall G, Allgen LG. Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependent diabetes. Acta Endocrinol Suppl (Copenh), 1980,239:6\u20138","journal-title":"Acta Endocrinol Suppl (Copenh)"},{"issue":"4","key":"1063_CR68","first-page":"206","volume":"10","author":"H.M. Tian","year":"1989","unstructured":"Tian HM, Liang JZ, Li Y, et al. Effects of aspirin on plasma glucose and platelet for diabetic patients. Sichuan Med J (Chinese), 1989,10(4):206\u2013207","journal-title":"Sichuan Med J (Chinese)"},{"issue":"3","key":"1063_CR69","first-page":"232","volume":"22","author":"J. Yu","year":"2008","unstructured":"Yu J, Wan J, Pan ZQ. Effects of fluvastatin and aspirin on C-reactive protein for old people with coronary heart disease and type 2 diabetes. Prac Geriat J (Chinese), 2008,22(3):232\u2013234","journal-title":"Prac Geriat J (Chinese)"},{"issue":"6","key":"1063_CR70","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2265.1984.tb01407.x","volume":"21","author":"E.P. Brass","year":"1984","unstructured":"Brass EP, Halter JB, Ensinck JW, et al. Effect of sodium salicylate on hormonal responses to hypoglycaemia in type II diabetics. Clin Endocrinol (Oxf), 1984,21(6): 649\u2013655","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1063_CR71","first-page":"750","volume":"27","author":"M. Chen","year":"1978","unstructured":"Chen M, Robertson RP. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes, 1978,27(7):750\u2013756","journal-title":"A glucose dose-related phenomenon. Diabetes"},{"key":"1063_CR72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00000441-196304000-00009","volume":"245","author":"S.G. Gilgore","year":"1963","unstructured":"Gilgore SG, Drew WL, Rupp JJ. The effect of salicylate on plasma nonesterified fatty acids. Am J Med Sci, 1963,245:456\u2013458","journal-title":"Am J Med Sci"},{"issue":"11","key":"1063_CR73","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0026-0495(81)90049-4","volume":"30","author":"J.R. McRae","year":"1981","unstructured":"McRae JR, Metz SA, Robertson RP. A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics. Metabolism, 1981,30(11):1065\u20131075","journal-title":"Metabolism"},{"issue":"25","key":"1063_CR74","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"J.R. Vane","year":"1971","unstructured":"Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971,231(25):232\u2013235","journal-title":"Nat New Biol"},{"issue":"17","key":"1063_CR75","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/01.CIR.102.17.2022","volume":"102","author":"K.K. Wu","year":"2000","unstructured":"Wu KK. Aspirin and salicylate: An old remedy with a new twist. Circulation, 2000,102(17):2022\u20132023","journal-title":"Circulation"},{"issue":"6706","key":"1063_CR76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","volume":"396","author":"M.J. Yin","year":"1998","unstructured":"Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 1998, 396(6706):77\u201380","journal-title":"Nature"},{"issue":"5174","key":"1063_CR77","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","volume":"265","author":"E. Kopp","year":"1994","unstructured":"Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 1994,265(5174):956\u2013959","journal-title":"Science"},{"issue":"5535","key":"1063_CR78","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1126\/science.1061620","volume":"293","author":"M. Yuan","year":"2001","unstructured":"Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 2001,293(5535):1673\u20131677","journal-title":"Science"},{"issue":"10","key":"1063_CR79","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.156.10.3961","volume":"156","author":"J.W. Pierce","year":"1996","unstructured":"Pierce JW, Read MA, Ding H, et al. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol, 1996,156(10):3961\u20133969","journal-title":"J Immunol"},{"issue":"5","key":"1063_CR80","doi-asserted-by":"crossref","first-page":"E1205","DOI":"10.1152\/ajpendo.00313.2009","volume":"297","author":"C. Xiao","year":"2009","unstructured":"Xiao C, Giacca A, Lewis GF. The effect of high-dose sodium salicylate on chronically elevated plasma non-esterified fatty acid-induced insulin resistance and beta cell dysfunction. Am J Physiol Endocrinol Metab, 2009,297(5):E1205\u20131211","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Journal of Huazhong University of Science and Technology [Medical Sciences]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-013-1063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-013-1063-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-013-1063-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T09:39:21Z","timestamp":1688031561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-013-1063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s11596-013-1063-5","relation":{},"ISSN":["1672-0733","1993-1352"],"issn-type":[{"value":"1672-0733","type":"print"},{"value":"1993-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}